2nd Materially Positive Event in Recent Months: OSRH announced global interest to license/distribute its Woori IO non-invasive glucose monitor. Of note, an NDA has been signed with giant Sinopharm that dominates the fast-growing Chinese diabetes care market. This announcement is the 2nd material event in recent months to underscore management’s credibility, due diligence validation, and downstream commercial optionality (i.e., global multi-center regulatory testing and licensing structure). Complementing this momentum, the Company is expected to imminently sign the definitive agreement with BCME to license development of VXM01 with a milestone value up to $815 million while capturing the deal value at the parent (OSRH) level.
